Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molibresib + Abiraterone or Enzalutamide in CRPC
NCT03150056Phase 1Terminated
- Sponsor
- GSK
- Start
- Jul 2017
- Primary completion
- Jul 2020
- Modality
- Allosteric Modulators
- Countries
- 4
01
Overview
Phase 1, open-label trial of molibresib in prostate cancer (PCa) (2 arms), sponsored by GSK. Primary endpoints: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 21.3 months, Number of Participants With AEs Leading to Any Dose Reduction or Delays up to 21.3 months and 2 more. Started Jul 2017; status: terminated.
02
Drugs
molibresib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03150056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150056.